Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J (JNJ) Recalls Some Sunscreens Due to Benzene Presence

by Zacks Equity Research

J&J (JNJ) withdraws five aerosol sunscreen products from the market due to "low levels" of benzene found in some samples.

AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition

by Zacks Equity Research

AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.

Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data

by Zacks Equity Research

Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

by Zacks Equity Research

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study

by Zacks Equity Research

Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.

Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

by Zacks Equity Research

The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.

WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara

by Zacks Equity Research

The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.

3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now

by Zacks Equity Research

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.

Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda

by Zacks Equity Research

Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates

by Kinjel Shah

EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.

Exelixis (EXEL) Down on Data from Ongoing Liver Cancer Study

by Zacks Equity Research

Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.

BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) new MAA in EU includes 52 weeks' data from the phase III GENEr8-1 study, along with four and three-year follow-up data from the ongoing phase I/II dose escalation study.

Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19

by Zacks Equity Research

The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.

Roche's (RHHBY) BLA for PDS With Ranibizumab Accepted by FDA

by Zacks Equity Research

The FDA accepts and grants Priority Review to Roche's (RHHBY) application for Port Delivery System with ranibizumab for the treatment of nAMD.

Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment

by Zacks Equity Research

Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.

Sheraz Mian headshot

Top Analyst Reports for AT&T, Walmart & Cisco

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Walmart (WMT), and Cisco (CSCO).

Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug

by Zacks Equity Research

Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.

Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

by Zacks Equity Research

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

by Zacks Equity Research

Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.

Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic

by Zacks Equity Research

Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.

argenx (ARGX) to Regain AML Candidate After J&J's Dismissal

by Zacks Equity Research

argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.

Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab

by Zacks Equity Research

FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Novartis (NVS) Announces Data on Radioligand Therapy at ASCO

by Zacks Equity Research

Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.

Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma

by Zacks Equity Research

The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Yervoy for the first-line treatment of malignant pleural mesothelioma.